Novel agents in relapsed/refractory diffuse large B-cell lymphoma.

Varma, Gaurav; Goldstein, Jordan; Advani, Ranjana H

Varma, Gaurav; Goldstein, Jordan; Advani, Ranjana H.

Affiliation

Varma G; Division of Hematology and Medical Oncology, Department of Medicine, New York University Grossman School of Medicine, New York, New York, USA.
Goldstein J; Department of Medicine, Division of Oncology, Stanford University, Stanford, California, USA.
Advani RH; Department of Medicine, Division of Oncology, Stanford University, Stanford, California, USA.

Hematol Oncol ; 41 Suppl 1: 92-106, 2023 Jun.

Article in En | MEDLINE | ID: mdl-37294966

Subject(s)

Immunoconjugates; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Humans; Antineoplastic Combined Chemotherapy Protocols; Immunoconjugates/therapeutic use; Lymphoma, Large B-Cell, Diffuse/drug therapy; Lymphoma, Large B-Cell, Diffuse/etiology; Lymphoma, Non-Hodgkin/drug therapy; Neoplasm Recurrence, Local/drug therapy; Tumor Microenvironment

Key words

DLBCL; novel agents; relapsed/refractory

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Lymphoma, Non-Hodgkin / Lymphoma, Large B-Cell, Diffuse / Immunoconjugates Type of study: Etiology_studies Limits: Humans Language: En Journal: Hematol Oncol Year: 2023 Type: Article Affiliation country: United States

Fulltext

XML

PubMed Links

Search on Google